These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24256238)

  • 1. The Cmr complex: an RNA-guided endoribonuclease.
    Bailey S
    Biochem Soc Trans; 2013 Dec; 41(6):1464-7. PubMed ID: 24256238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-activated DNA cleavage by the Type III-B CRISPR-Cas effector complex.
    Estrella MA; Kuo FT; Bailey S
    Genes Dev; 2016 Feb; 30(4):460-70. PubMed ID: 26848046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirements for a successful defence reaction by the CRISPR-Cas subtype I-B system.
    Stoll B; Maier LK; Lange SJ; Brendel J; Fischer S; Backofen R; Marchfelder A
    Biochem Soc Trans; 2013 Dec; 41(6):1444-8. PubMed ID: 24256235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservation and variability in the structure and function of the Cas5d endoribonuclease in the CRISPR-mediated microbial immune system.
    Koo Y; Ka D; Kim EJ; Suh N; Bae E
    J Mol Biol; 2013 Oct; 425(20):3799-810. PubMed ID: 23500492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting it close: CRISPR-associated endoribonuclease structure and function.
    Hochstrasser ML; Doudna JA
    Trends Biochem Sci; 2015 Jan; 40(1):58-66. PubMed ID: 25468820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hot and crispy: CRISPR-Cas systems in the hyperthermophile Sulfolobus solfataricus.
    Zhang J; White MF
    Biochem Soc Trans; 2013 Dec; 41(6):1422-6. PubMed ID: 24256231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The subtype I-F CRISPR-Cas system influences pathogenicity island retention in Pectobacterium atrosepticum via crRNA generation and Csy complex formation.
    Richter C; Fineran PC
    Biochem Soc Trans; 2013 Dec; 41(6):1468-74. PubMed ID: 24256239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type III CRISPR-Cas Immunity: Major Differences Brushed Aside.
    Tamulaitis G; Venclovas Č; Siksnys V
    Trends Microbiol; 2017 Jan; 25(1):49-61. PubMed ID: 27773522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RNA- and DNA-targeting CRISPR-Cas immune systems of Pyrococcus furiosus.
    Terns RM; Terns MP
    Biochem Soc Trans; 2013 Dec; 41(6):1416-21. PubMed ID: 24256230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CRISPR-associated Csx1 protein of Pyrococcus furiosus is an adenosine-specific endoribonuclease.
    Sheppard NF; Glover CV; Terns RM; Terns MP
    RNA; 2016 Feb; 22(2):216-24. PubMed ID: 26647461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA and RNA interference mechanisms by CRISPR-Cas surveillance complexes.
    Plagens A; Richter H; Charpentier E; Randau L
    FEMS Microbiol Rev; 2015 May; 39(3):442-63. PubMed ID: 25934119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of the Cmr2-Cmr3 subcomplex in the CRISPR-Cas RNA silencing effector complex.
    Osawa T; Inanaga H; Numata T
    J Mol Biol; 2013 Oct; 425(20):3811-23. PubMed ID: 23583914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A type III-B CRISPR-Cas effector complex mediating massive target DNA destruction.
    Han W; Li Y; Deng L; Feng M; Peng W; Hallstrøm S; Zhang J; Peng N; Liang YX; White MF; She Q
    Nucleic Acids Res; 2017 Feb; 45(4):1983-1993. PubMed ID: 27986854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted mutagenesis in Zea mays using TALENs and the CRISPR/Cas system.
    Liang Z; Zhang K; Chen K; Gao C
    J Genet Genomics; 2014 Feb; 41(2):63-8. PubMed ID: 24576457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas: From the Bacterial Adaptive Immune System to a Versatile Tool for Genome Engineering.
    Kirchner M; Schneider S
    Angew Chem Int Ed Engl; 2015 Nov; 54(46):13508-14. PubMed ID: 26382836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cas6 specificity and CRISPR RNA loading in a complex CRISPR-Cas system.
    Sokolowski RD; Graham S; White MF
    Nucleic Acids Res; 2014 Jun; 42(10):6532-41. PubMed ID: 24753403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptation in bacterial CRISPR-Cas immunity can be driven by defective phages.
    Hynes AP; Villion M; Moineau S
    Nat Commun; 2014 Jul; 5():4399. PubMed ID: 25056268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity.
    Samai P; Pyenson N; Jiang W; Goldberg GW; Hatoum-Aslan A; Marraffini LA
    Cell; 2015 May; 161(5):1164-1174. PubMed ID: 25959775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cmr1 enables efficient RNA and DNA interference of a III-B CRISPR-Cas system by binding to target RNA and crRNA.
    Li Y; Zhang Y; Lin J; Pan S; Han W; Peng N; Liang YX; She Q
    Nucleic Acids Res; 2017 Nov; 45(19):11305-11314. PubMed ID: 28977458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolutionary causes and consequences of diversified CRISPR immune profiles in natural populations.
    England WE; Whitaker RJ
    Biochem Soc Trans; 2013 Dec; 41(6):1431-6. PubMed ID: 24256233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.